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Abstract
Background: Neuropsychiatric side effects of oseltamivir occur occasionally, especially in infants and young
patients, but nothing is known about possible contributory factors.
Case presentation: We report a case of a 15-year-old Japanese female with influenza infection who developed
abnormal psychiatric symptoms after administration of standard doses of oseltamivir. She had no history of
neurological illness, had never previously taken oseltamivir, and had not developed psychiatric reactions during
previous influenza infection. Her delirium-like symptoms, including insomnia, visual hallucinations, and a long-term
memory deficit, disappeared after cessation of oseltamivir and administration of benzodiazepine. Detailed assessment
was performed, including neurological examination (electroencephalogram, brain magnetic resonance imaging, single
photon emission computed tomography with 99mTc-ethyl cysteinate dimer and with 123I-iomazenil, cerebrospinal
fluid analysis and glutamate receptor autoantibodies), drug level determination and simulation, and genetic
assessment (OAT1, OAT3, CES1, Neu2).
Conclusions: Abnormal slowing in the electroencephalogram, which is characteristic of influenza-associated
encephalopathy, was not observed in repeated recordings. The serum level determination of active metabolite Ro
64-0802 determined at 154 h after final dosing of oseltamivir was higher than the expected value, suggesting delayed
elimination of Ro 64-0802. Thus, abnormal exposure to Ro 64-0802 might have contributed, at least in part, to the
development of neuropsychiatric symptoms in this patient. The score on Naranjo’s adverse drug reaction probability
scale was 6. Mutation of c.122G > A (R41Q) in the sialidase Neu2 gene, increased CSF glutamate receptor
autoantibodies, and limbic GABAergic dysfunction indicated by SPECT with 123I-iomazenil were found as possible
contributory factors to the CNS side effects.
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Background
Oseltamivir is a prodrug of the neuraminidase inhibitor
[3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-carboxylic acid (Ro 64-0802), which tar-
gets the influenza virus. Despite good tolerance of this
drug by most patients, there have been reports of
neuropsychiatric side effects, especially in infants and
young patients [1]. However, contributory factors to
the development of neuropsychiatric reactions after
administration of oseltamivir are presently unknown.
Case presentation
This previously healthy 15-year-old Japanese girl devel-
oped fever and was diagnosed with influenza A virus in-
fection based on a positive result with a rapid detection
kit in 2009, during the pandemic influenza (H1N1)
period. She had not previously taken oseltamivir, and
had not developed neuropsychiatric symptoms in her
previous influenza infection; this was her first admission
to a neurological ward. The day after oseltamivir was
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started, her fever subsided, but the family noticed un-
usual behavior, such as doing her makeup at midnight
and littering her room. She took 5 doses of 2 mg/kg
(150 mg/day, b.i.d., 36 kg in weight) of oseltamivir every
twelve hours and concomitantly took dihydrocodeine,
ambroxol, benproperine, azithromycin and clarithromycin.
There is no report of neuropsychiatric symptoms associ-
ated with these concomitant medications, except clari-
thromycin (clarithromycin occasionally induces altered
mental status accompanied with electroencephalogram
(EEG) abnormality, mostly in adults with psychiatric ill-
ness [2]). The symptoms did not fluctuate according to
oseltamivir dosing times. After 3 days, she suddenly left
her home and was found standing in front of an unknown
apartment. Her family discontinued oseltamivir at that
point. Because her bizarre behaviors continued after cessa-
tion of oseltamivir (for example, she complained of hear-
ing voices of strange men), she was admitted to our
hospital with suspected influenza encephalopathy. She de-
veloped delirium-like symptoms, such as insomnia, dis-
orientation, visual hallucinations, a long-term memory
deficit, abnormal behaviors (e.g., persistent ritual sneezing)
and delusion (e.g., insisting that she was pregnant), but
showed normal responses intermittently, especially during
benzodiazepine infusion (diazepam or midazolam). Mid-
azolam infusion (1 mg) enabled her to give correct verbal
responses to questions about her name, her friends’
names, her age, and her address, as well as to perform
mental calculations (additions and subtractions). Seizures
were not observed and abnormal slowing in the EEG,
which is characteristic of influenza-associated encephalop-
athy, was not observed in repeated recordings. Cerebro-
spinal fluid (CSF) study and repeated brain MRIs showed
no abnormality. SPECT with 99mTc-ethyl cysteinate dimer
showed no abnormal cerebral perfusion, while SPECT
with 123I-iomazenil (performed 3 days after discontinu-
ation of benzodiazepine) showed decreased benzodiazep-
ine receptor binding in the right medial temporal area
(Fig. 1).
Glutamate receptor autoantibodies (GluRAbs), including
GluRε2-NT2, GluRε2-CT1, GluRδ2-NT and GluRδ2-CT,
were within normal limits in serum, but were increased in
CSF (Additional file 1: Table S1).
Finally, she completely recovered within 2 weeks after
cessation of oseltamivir and administration of benzodi-
azepine (oral nitrazepam or lorazepam, with continuous
midazolam infusion for 5 days in the middle). Naranjo’s
adverse drug reaction probability scale [3] gave a score
of 6.
Drug level determination and simulation
At 154 h after final dosing of oseltamivir, blood and
cerebrospinal fluid (CSF) were taken for drug level de-
termination and genetic assessment. The serum level of
oseltamivir was under the detection limit (0.5 ng/mL)
and that of its active metabolite Ro 64-0802 was
1.30 ng/mL. CSF levels of oseltamivir and Ro 64-0802
were both under the detection limit (0.5 ng/mL). The
observed serum level of Ro 64-0802 in this patient was
higher than the expected level of Ro 64-0802 based on
the pharmacokinetic parameters of age-matched healthy
subjects, suggesting delayed excretion of Ro 64-0802
(Fig. 2a). The pharmacokinetics of oseltamivir in patients
with influenza is qualitatively similar to that in healthy
subjects [4].
Oseltamivir is exclusively converted by hepatic carbox-
ylesterase CES1 to Ro 64-0802, which is excreted into
urine by glomerular filtration and tubular secretion via
organic anion transporter OAT1 and/or OAT3 [5, 6].
Delayed excretion of Ro 64-0802 could be due either to
decreased conversion of oseltamivir to Ro 64-0802 or to
decreased elimination of Ro 64-0802 itself. Simulation
studies indicated that the observed serum concentration
of Ro 64-0802 at 154 h after final dosing was consistent
with a decrease to one-tenth of normal in the conversion
rate of oseltamivir to Ro 64-0802 or with a decrease to
one-half in the elimination rate of Ro 64-0802 (Fig. 2b,
Additional file 2: Table S2 and Additional file 3: Table S3).
The former case, but not the latter, would also result in
increased concentrations of oseltamivir, though in both
cases, the oseltamivir concentration would have been at
an undetectable level by 154 h after the final dose. The
patient’s renal function was normal. The patient was
not receiving any drugs known to inhibit OAT1, OAT3
or CES1.
Genetic assessment
Gene sequencing of OAT1 and OAT3 and diplotype ana-
lysis of CES1 failed to explain her abnormal exposure to
Ro 64-0802. Examination of the single nucleotide poly-
morphism of c.122G > A(R41Q) in the human sialidase
Neu2 gene showed that the patient was a heterozygous
carrier of this variation [7].
R
123I-IMZ SPECT
Fig. 1 SPECT with 123I-iomazenil 10 days after admission revealed
decreased benzodiazepine receptor binding in the right medial
temporal area (arrows)
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Discussion and conclusions
As far as we know, this is the first case report that in-
cludes the results of a comprehensive examination of
the underlying mechanisms of psychiatric reactions as-
sociated with oseltamivir. The results of drug level de-
termination and simulation suggested that enhanced
exposure to either Ro 64-0802 alone or to both oselta-
mivir and Ro 64-0802 might have occurred in this case.
Although influenza encephalopathy itself causes simi-
lar symptoms, and it was ethically unacceptable to
examine the effect of re-administration of oseltamivir,
this neuropsychiatric reaction appears to have been
drug-induced, because EEG changes characteristic of
influenza-associated encephalopathy was not observed
and the symptoms disappeared after drug cessation. A
previous report indicated that oseltamivir up to 450 mg
twice daily is well-tolerated in healthy volunteers, and no
drug-related psychiatric symptoms were observed [8].
However, the safety and pharmacokinetics of oseltamivir
and Ro 64-0802 in subjects with severe influenza infection
are presently unknown. In our patient, repeated measure-
ments of the same samples and simulation studies clearly
demonstrated enhanced exposure to Ro 64-0802, although
the precise reason for this was not established. The brain
concentration of oseltamivir and/or Ro 64-0802 is likely to
be the key determinant of neuropsychiatric side effects.
Although oseltamivir and Ro 64-0802 were not detected
in CSF, it is considered that enhanced brain exposure to
oseltamivir and/or Ro-64-0802 would have occurred, be-
cause brain-to-plasma ratios were reported to be linear up
to 100 mg/kg (with values of 0.1 for oseltamivir and
0.005–0.02 for Ro 64-0802) in mice [9]. Efflux transport of
oseltamivir is mediated by P-glycoprotein (ABCB1) at the
blood–brain barrier, and therefore reduced P-glycoprotein
activity due to factors such as genetic polymorphism
[10] and inhibition by pro-inflammatory cytokines [11]
or concomitant drugs could result in an increased brain
concentration of oseltamivir. For example, our patient
concomitantly received azithromycin, which may in-
hibit P-glycoprotein [12]. Although Ro 64-0802 is not a
substrate of P-glycoprotein, animal studies indicate that
it undergoes active efflux at the BBB mediated by trans-
porter(s) such as OAT3 [13]. Therefore, reduced efflux
transport of Ro 64-0802 is another possibility, although
no genetic abnormality of OAT3 was found in our patient.
Based on the neuropsychiatric symptoms following
influenza A infection and the increase in CSF GluRAb,
our patient's clinical course could be categorized as non-
herpetic limbic encephalitis [14], but the precise noso-
logical position remains inconclusive. Our patient’s clinical
course somewhat resembled that of autoimmune limbic
encephalitis, but differed in disease duration (much longer
in autoimmune limbic encephalitis), the efficacy of benzo-
diazepine, the absence of abnormal EEG and CSF findings,
and the absence of seizures and movement disorders dur-
ing the clinical course (seizures and movement disorders
are often observed in patients with typical autoimmune
limbic encephalitis according to Dalmau’s group [15, 16]).
Further, our GluRAbs were different from Dalmau’s
NR1/NR2 heteromers of N-methyl-Daspartate receptor
(NMDAR), and the disease sensitivity of our GluRAbs
appeared to be low.
Limbic GABAergic dysfunction might be involved in
the pathogenesis, considering the transience of the
symptoms and the later persistent efficacy of benzodi-


































































Fig. 2 Simulations of serum concentrations of oseltamivir and Ro 64-0802. a Simulation with normal parameters. Closed circle (arrow), observed
Ro 64-0802 concentration; dotted line, simulated oseltamivir concentration; solid line, simulated Ro 64-0802 concentration. b Simulations of Ro
64-0802 and oseltamivir concentrations. Closed circle (arrow), observed Ro 64-0802 concentration; dotted lines, oseltamivir; solid lines, Ro 64-0802.
Thin lines indicate simulation results using an elimination rate of Ro 64-0802 of one-half of the normal value. Bold lines indicate simulation results
using a conversion rate of oseltamivir to Ro 64-0802 of one-tenth of the normal value
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the 123I-IMZ SPECT findings, which suggested a decrease
in the right medial temporal benzodiazepine/GABA-A re-
ceptors. Usami et al. [17] reported that oseltamivir and its
active metabolite enhanced neuronal synchronization and
induced population burst events of rat hippocampal CA3
networks in a concentration-dependent manner. They
suggested that the oseltamivir-induced population bursts
may be shaped by the phasic activity of inhibitory inter-
neurons, rather than pyramidal cells. Thus, GABAergic in-
hibitory interneurons might be an action target of
oseltamivir.
The genetic polymorphism of c.122G > A (R41Q) in
the Neu2 gene of our patient resides near the active site
of this enzyme and has the effect of increasing the binding
affinity of Ro 64-0802, making the enzyme more sensitive
to inhibition by Ro 64-0802 in vitro [4]. We speculate that
oseltamivir induced excessive population bursts, which
were further enhanced by the Neu2 gene SNP, result-
ing in down-regulation of GABAergic receptor, leading
to the SPECT change. Because of the similarity be-
tween the neuropsychiatric reaction to oseltamivir and
the symptoms of human sialidase-related disorders
(epilepsy [18], seizures [19], mental deterioration [20],
impaired intelligence [20]) and the role of sialidases
in neuronal excitation [21, 22] and synaptic plasticity
[23], we speculate that possession of this variant may
play a role in the occurrence of severe adverse reac-
tions to oseltamivir. Further clinical investigation will
be needed to test this idea.
In conclusion, abnormal exposure to oseltamivir and/or
Ro 64-0802 probably contributed to the development of
neuropsychiatric symptoms in this patient, at least in part.
Factors that might increase the risk of CNS side effects
after administration of oseltamivir include Neu2 muta-
tion, exclusively observed in Asians, and increased CSF
GluRAbs. GABAergic inhibitory neurons may play an
important role in the pathogenesis of the psychiatric
symptoms.
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